Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation

Immune-mediated colitis is an uncommon but well-documented adverse event in patients receiving nivolumab or ipilimumab therapy. In this report, we present a 69-year-old man who developed severe hypokalemia and colitis with significant corrected Q-T segment (QTc) prolongation as a result of combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Anson, David, Norton, Joseph, Chaucer, Benjamin, Bansal, Saurabh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948332/
https://www.ncbi.nlm.nih.gov/pubmed/31949966
http://dx.doi.org/10.1155/2019/7896749
_version_ 1783485726253383680
author Anson, David
Norton, Joseph
Chaucer, Benjamin
Bansal, Saurabh
author_facet Anson, David
Norton, Joseph
Chaucer, Benjamin
Bansal, Saurabh
author_sort Anson, David
collection PubMed
description Immune-mediated colitis is an uncommon but well-documented adverse event in patients receiving nivolumab or ipilimumab therapy. In this report, we present a 69-year-old man who developed severe hypokalemia and colitis with significant corrected Q-T segment (QTc) prolongation as a result of combination nivolumab-ipilimumab immunotherapy for clear cell renal cell carcinoma.
format Online
Article
Text
id pubmed-6948332
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-69483322020-01-16 Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation Anson, David Norton, Joseph Chaucer, Benjamin Bansal, Saurabh Case Rep Oncol Med Case Report Immune-mediated colitis is an uncommon but well-documented adverse event in patients receiving nivolumab or ipilimumab therapy. In this report, we present a 69-year-old man who developed severe hypokalemia and colitis with significant corrected Q-T segment (QTc) prolongation as a result of combination nivolumab-ipilimumab immunotherapy for clear cell renal cell carcinoma. Hindawi 2019-12-26 /pmc/articles/PMC6948332/ /pubmed/31949966 http://dx.doi.org/10.1155/2019/7896749 Text en Copyright © 2019 David Anson et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Anson, David
Norton, Joseph
Chaucer, Benjamin
Bansal, Saurabh
Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
title Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
title_full Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
title_fullStr Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
title_full_unstemmed Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
title_short Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
title_sort ipilimumab- and nivolumab-induced colitis causing severe hypokalemia and qtc prolongation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948332/
https://www.ncbi.nlm.nih.gov/pubmed/31949966
http://dx.doi.org/10.1155/2019/7896749
work_keys_str_mv AT ansondavid ipilimumabandnivolumabinducedcolitiscausingseverehypokalemiaandqtcprolongation
AT nortonjoseph ipilimumabandnivolumabinducedcolitiscausingseverehypokalemiaandqtcprolongation
AT chaucerbenjamin ipilimumabandnivolumabinducedcolitiscausingseverehypokalemiaandqtcprolongation
AT bansalsaurabh ipilimumabandnivolumabinducedcolitiscausingseverehypokalemiaandqtcprolongation

Ejemplares similares